Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.

Saah AJ, Haas DW, DiNubile MJ, Chen J, Holder DJ, Rhodes RR, Shivaprakash M, Bakshi KK, Danovich RM, Graham DJ, Condra JH
J Infect Dis. 2003 187 (7): 1157-62

PMID: 12660932 · DOI:10.1086/368287

A prospective, open-label study was conducted to assess the response to indinavir, efavirenz, and adefovir in human immunodeficiency virus (HIV)-infected patients experiencing viral rebound while receiving therapy with nelfinavir-containing regimens, to determine whether the protease genotype influenced the outcome of the salvage regimen. Genotyping from 29 nelfinavir failures revealed D30N in 17 (59%) and L90M in 11 (38%) cases. Suppression to <400 viral RNA copies/mL was achieved at week 48 in 56% of patients with the D30N virus versus 18% of patients with the L90M virus.

MeSH Terms (17)

Adenine Adult Anti-HIV Agents Benzoxazines Drug Resistance, Viral Female HIV HIV Infections HIV Protease Inhibitors Humans Indinavir Male Middle Aged Nelfinavir Organophosphonates Oxazines Treatment Failure

Connections (1)

This publication is referenced by other Labnodes entities: